Acute Lymphoblastic Leukemia Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The application of targeted RNA sequencing for the analysis of fusion genes, gene mutations, IKZF1 intragenic deletion, and CRLF2 overexpression in acute lymphoblastic leukemia
CONCLUSION: The utilization of RNA-seq enables the identification of clinically significant genetic abnormalities that may go undetected through conventional detection methods. Its robust analytical performance might bring great application value for clinical diagnosis, prognosis, and therapy in ALL.PMID:38553845 | DOI:10.1111/ijlh.14269 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - March 30, 2024 Category: Hematology Authors: Zhenyu Zhang Yu Jing Bin Chen Hong Zhang Tuo Liu Shuran Dong Lei Zhang Xiaoyan Yan Shaobin Yang Long Chen Yani Lin Kun Ru Source Type: research

Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia
CONCLUSION: The pharmacokinetics of PEGasparaginase in infants diagnosed under one year of age with ALL is comparable to that of older children (1-18 years). We recommend a PEGasparaginase dosing at 1,500 IU/m2 for infants without dose adaptations according to age, and implementing therapeutic drug monitoring as standard practice.PMID:38538970 | DOI:10.1007/s11095-024-03693-3 (Source: Cell Research)
Source: Cell Research - March 28, 2024 Category: Cytology Authors: Leiah J Brigitha Veerle Mondelaers Yiwei Liu Birgitte K Albertsen Beata Zalewska-Szewczyk Carmelo Rizzari Rishi S Kotecha Rob Pieters Alwin D R Huitema Inge M van der Sluis Source Type: research

Extracellular matrix protein 1 (ECM1) is a potential biomarker in B cell acute lymphoblastic leukemia
AbstractB cell acute lymphoblastic leukemia (ALL) is characterized by the highly heterogeneity of pathogenic genetic background, and there are still approximately 30 –40% of patients without clear molecular markers. To identify the dysregulated genes in B cell ALL, we screened 30 newly diagnosed B cell ALL patients and 10 donors by gene expression profiling chip. We found thatECM1 transcription level was abnormally elevated in newly diagnosed B cell ALL and further verified in another 267 cases compared with donors (median, 124.57% vs. 7.14%,P < 0.001). ROC analysis showed that the area under the curve ofECM1 tra...
Source: Clinical and Experimental Medicine - March 28, 2024 Category: Research Source Type: research